Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives.

With a seasoned leadership team with world-class expertise spanning research, clinical development, regulatory, manufacturing and commercial experience in hematologic …

Dec 11, 2025 · Geron is a commercial-stage biopharmaceutical company with a first-in-class telomerase inhibitor that is approved in the United States for the treatment of certain adult …

Geron is always accepting applications for employment opportunities. Click on the ‘ Explore Open Positions ’ link above to find all of the open positions for which we are currently recruiting.

Geron is exploring the broad potential of telomerase inhibition across multiple myeloid hematologic malignancies.

Nov 5, 2025 · Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent …

Geron is founded by Mike West, a pioneer in stem cell, cellular aging and telomerase research, and Alex Barkas, a venture capitalist who at the time was a partner at Kleiner Perkins Caufield …

Geron is a commercial stage biopharmaceutical company commercializing a first-in-class telomerase inhibitor for relapsed/refractory myelodysplastic syndromes.

Aug 6, 2025 · Mr. Semerjian will succeed Dawn Carter Bir, who has served as Interim President and CEO since March 2025. Ms. Bir will continue in her role on Geron’s Board of Directors, …

Geron sponsored trials IMpactMF, our pivotal Phase 3 clinical trial in JAK inhibitor relapsed/refractory MF, is an open label, 2:1 randomized, controlled clinical trial of imetelstat …